SCHEMBL7095640

SCHEMBL7095640

Cc1ccc(CC(NC(=O)OC(C)(C)C)c2ccc3c(c2)NC(=S)C(C)O3)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.37
HPGD P15428 5/20 0.37
HTT P42858 5/20 0.37
NPSR1 Q6W5P4 5/20 0.37
LMNA P02545 4/20 0.37
PKM P14618 3/20 0.37
KMT2A Q03164 2/20 0.37
JAK2 O60674 2/20 0.37
PTPRB P23467 2/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
TSHR P16473 3/20 0.35
HSD17B10 Q99714 2/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 2/20 0.35
TP53 P04637 2/20 0.35
AGTR1 P30556 1/20 0.35
RAB9A P51151 1/20 0.35
RCE1 Q9Y256 1/20 0.35
XBP1 P17861 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7087725 0.92 CTSS (0.41) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL7092472 0.92 HSD17B10 (0.37) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL7704943 0.92 ALDH1A1 (0.43) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL7094044 0.91 SMN1; SMN2 (0.40) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL7092669 0.91 CTSS (0.34) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL7713294 0.90 PARP1 (0.42) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL7093832 0.90 PTPRB (0.37) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL7710783 0.89 PPARG (0.39) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL7095139 0.89 CA2 (0.41) ALDH1A1HPGDHTTNPSR1LMNA
SCHEMBL7091267 0.89 HSD17B10 (0.33) ALDH1A1HPGDHTTNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed